Molika Ashford covers personalized medicine and molecular diagnostics for GenomeWeb.
The company is continuing to collect utility and cost effectiveness data for its SelectMDx test in reducing unnecessary procedures in men with signs of a possible prostate cancer.
Results of the study, published in JAMA, highlight ongoing and future challenges in translating the promise of comprehensive genomics into clinical benefit.
The company highlighted growth in demand for its test , and is now ramping up marketing and focusing on its IVD development plans.
A Samsung University team found that mutation load measured with the Guardant360 liquid biopsy assay predicted response as well as tissue-based TMB.
The firm has collected evidence supporting the use of its PancraGen to providing the same molecular information for samples from biliary strictures and solid pancreatic lesions as it has done for years in pancreatic cyst fluid.
The company hopes to launch its first clinical cancer test within the next year, after spending the last several years conducting validation studies.
The company is confident about bringing the test to market despite potential future competition and views it as an easy fit for its existing sales channels.
Using a technology called optical stretching, investigators found that they could distinguish oral cancer cells from normal cells based on how soft or deformable they were.
A new trial has compared the two most prominent tests, showing that both have clear predictive ability, but leaving several other questions unanswered so far.
In a new analysis of the trial, researchers concluded that women over the age of 50 with recurrence scores below 25 appear to see no added benefit from adjuvant chemo.